Buruli ulcer (BU), caused by Mycobacterium ulcerans is currently treated by a daily 30 combination of rifampin and either injectable streptomycin or oral clarithromycin. An 31 intermittent oral regimen would facilitate the treatment supervision. We first evaluated 32 the bactericidal activity of newer antimicrobials against M. ulcerans using a BU animal 33 model. The imidazopyridine amine Q203 exhibited high bactericidal activity whereas 34 tedizolid (oxazolidinone close to linezolid), selamectine and ivermectine (avermectine 35 compound) and the benzothiazinone PBTZ169 were not active. Consequently, Q203 36 was evaluated for its bactericidal and sterilizing activities in combined intermittent 37 regimens. Q203 given twice a week in combination with one of the other long half-life 38 compounds, rifapentine or bedaquiline, sterilized the mice footpads in 8 weeks, i.e. 39 after a total of only 16 doses, and prevented relapse during a period of 20 weeks after 40 stopping the treatment. These results are very promising for future intermittent oral 41 regimens which would greatly simplify BU treatments in the field. 42 4 43
Introduction
. All untreated mice had culture-positive 193 footpads at the time of treatment start with a mean of 6.93 ± 0.20 log 10 CFUs, value 194 that remained unchanged at week 4. All mice remained culture positive after 4 weeks 195 of treatment in the RIF control-groups but the mean CFU counts was significantly lower 196 (p<0.05) than that in the untreated mice group (4.58 ± 1.29 log 10 for RIF and 2.15 ± 197 1.20 log 10 for RIF-STR, respectively). After 8 weeks of treatment, only 2 out of 8 mice 198 in the RIF groups remained culture positive with a low mean CFU counts (<1 log 10 ). (Table 2) . All untreated mice had culture-positive MICs remained unchanged against bacilli isolated from the 8 relapsing mice in the RIF-new shorter treatments of BU. In the present study, we demonstrated that double 352 combinations of Q203 at 5 mg/kg with either RPT or BDQ, thanks to the long half-life 353 and good bio availabilities of these drugs, provided very promising results for future 354 fully oral intermittent regimens which would greatly simplify BU treatments in the field.
